this post was submitted on 10 Oct 2024
84 points (91.2% liked)

Technology

59357 readers
4030 users here now

This is a most excellent place for technology news and articles.


Our Rules


  1. Follow the lemmy.world rules.
  2. Only tech related content.
  3. Be excellent to each another!
  4. Mod approved content bots can post up to 10 articles per day.
  5. Threads asking for personal tech support may be deleted.
  6. Politics threads may be removed.
  7. No memes allowed as posts, OK to post as comments.
  8. Only approved bots from the list below, to ask if your bot can be added please contact us.
  9. Check for duplicates before posting, duplicates may be removed

Approved Bots


founded 1 year ago
MODERATORS
 

The immune-suppressing drug rapamycin, originally used for kidney transplants, is gaining attention for its potential to slow aging.

you are viewing a single comment's thread
view the rest of the comments
[–] Soulcreator@lemmy.world 14 points 1 month ago (1 children)

See that's the interesting thing about rapamycin, it's an old drug that has been used for immuno-suppression for years now, only just now scientists are discovering this interesting side effect. The patient on rapamycin has expired so you can get a generic prescription for cheap.

But ironically because the patent expired there's no money in it for the drug companies to get it approved for longevity purposes, so who knows if it will ever become approved for this purpose.

[–] ikidd@lemmy.world 6 points 1 month ago (1 children)

There are one or two countries outside the US that can approve drugs for use.

[–] Soulcreator@lemmy.world 1 points 1 month ago

Indeed there are, but just under half of all of medical studies performed world wide are performed in the States, roughly half of the world's pharmaceutical companies based in the States, and the US has consistently lead the world in medical innovations, with almost 50 percent more innovations than from the EU and Switzerland combined.

My point is not to sound US centric, but to say there is a lot of capital and willpower in the US pharmaceutical industry, and without that willpower it will be significantly harder to get rapamycin accepted as a viable longevity drug.